Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment

Mirum Pharmaceuticals (MIRM) has disclosed a new risk, in the Innovation / R&D category.

Mirum Pharmaceuticals faces a significant business risk with its drug Chenodal, which, although standard care for cerebrotendinous xanthomatosis (CTX), lacks FDA approval for this specific indication. The company’s inability to market or promote Chenodal for CTX curtails its revenue growth potential. Furthermore, the outcome of the RESTORE clinical trial and subsequent FDA response could lead to delays or denial of approval, jeopardizing potential orphan exclusivity and adversely affecting Mirum’s financial position. Any change in the FDA’s current stance on Chenodal’s off-label use could severely impact its sales for CTX treatment.

Overall, Wall Street has a Strong Buy consensus rating on MIRM stock based on 7 Buys.

To learn more about Mirum Pharmaceuticals’ risk factors, click here.